Ga68-Integrin (RAD301) selected for presentation at EANM

ASX ANNOUNCEMENT 27 SEPTEMBER 2022 Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889 Ga68-Integrin (RAD301) selected for oral presentation at European Association of Nuclear Medicine Annual Congress Radiopharm Theranostics (ASX:RAD) and TRIMT GmbH are pleased to announce that its Ga68- Integrin (RAD301) asset targeting pancreatic cancer has been selected for an oral presentation at the 35th Annual Congress of the European Association of Nuclear Medicine (EANM). Dr. Jana Rehm (University Hospital Carl Gustav Carus Dresden, Nuclear Medicine Dpt.) will present “PET/CT and PET/MR imaging with 68Ga-TVH in patients with pancreatic cancer - First clinical experience” within one of the top rated oral presentation sessions of the Scientific Program of EANM. The lecture (OP-546) will be given on Tuesday, October 18 at 8:45 a.m. in the Hall 112 within the session 1202 - TOP Trials Session 3: New Radiopharmaceutical Trials. Furthermore, the clinical evaluation of Ga68-Integrin in PDAC by the team of Prof. Dr. Jörg Kotzerke was selected also for the Congress Highlights. “We’re thrilled to see this independent endorsement highlighting the significance of our Trivehexin technology at a major radiopharmaceutical meeting, and we look forward to reporting continued progress of the program,” said Dr Jakub Simecek, CEO and Co-Founder of TRIMT. “It is a pleasure to see the excellent work of the medical team from Dresden receive this recognition by the EANM committee for their first translation of TRIMT´s Trivehexin (RAD301) in the clinical setup,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. EANM is held once a year and is a key meeting of nuclear medicine physicians, physicists and radiopharmacists/radiochemists, as well as other scientific and healthcare staff from Europe as well as worldwide. The meeting is strongly supported also by numerous industrial exhibitors with global footprint. Radiopharm Theranostics and TRIMT entered into an exclusive license agreeme nt in August 2021 to develop radiopharmaceuticals including Ga68-Integrin (RAD301). Authorised on behalf of the Radiopharm Theranostics board of directors by Chairman Paul Hopper. For more information: Riccardo Canevari CEO & Managing Director P: +1 862 309 0293 E: [email protected] Paul Hopper Executive Chairman P: +61 406 671 515 E: [email protected] ASX ANNOUNCEMENT 27 SEPTEMBER 2022 Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889 Media Matt Wright NWR Communications P: +61 451 896 420 E: [email protected] Follow Radiopharm Theranostics: Website – https://radiopharmtheranostics.com/ Twitter – https://twitter.com/TeamRadiopharm Linked In – https://www.linkedin.com/company/radiopharm-theranostics/ Contact TRIMT GmbH: Jakub Simecek CEO E: [email protected] Follow TRIMT: Website - www.trimt.de Linked In - www.linkedin.com/company/trimt-gmbh

The release as fetched from its publisher. radiopharmtheranostics.com ↗